Development of tinea corporis in a Japanese patient with atopic dermatitis under treatment with upadacitinib in a real‐world clinical setting: Possible contribution of the suppression of Th17

Abstract

We present a rare case of a patient with AD who developed tinea corporis during upadacitinib treatment in a real‐world clinical setting. We hypothesized that the suppressive effect of Th17 immunity by upadacitinib possibly has contributed to the development of tinea corporis.